There are a significant number of patients receiving drug-eluting stents and besides, require oral anticoagulation. The combination of anticoagulants, aspirin, and clopidogrel greatly increases the rate of bleeding, because of this, the time of the triple scheme should be as short as possible. The aim of this study was to compare the triple therapy for...
RIBS IV: Drug-eluting balloon versus everolimus-eluting stent on in-stent restenosis
This prospective, multicenter, randomized trial compared the paclitaxel-eluting balloon versus everolimus-eluting stent to treat patients with in-stent restenosis. 309 patients were included in total (154 received the drug-eluting balloon, and 155 received the everolimus-eluting stent). There were no differences in the characteristics of both groups. At one year the rate of cardiac death, myocardial infarction...
NOBORI II: Final 5-year results of drug-eluting stent with bio-absorbable polymer
This study evaluated the performance of Nobori biolimus bio-absorbable polymer stent in real-world patients. A total of 3067 consecutive patients followed up to 5 years were included. The rate of target lesion (composite of cardiac death, myocardial infarction and target lesion revascularization) was 3.9% at one year and 5.1% at 2 years. Long-term clinical performance...
COMPARE II: biolimus eluting stent with biodegradable polymer versus everolimus at 3 years.
This study randomized 2:1 – 2707 patients to biolimus eluting stent with biodegradable polymer versus everolimus eluting stent with permanent polymer. At one year, the results were similar demonstrating the biolimus eluting stent noninferiority. At three years cardiac death, myocardial infarction and target vessel revascularization rates remained similar with 11% for biolimus eluting stent and...
DESSOLVE II: 2-year results show the superiority of the sirolimus eluting stent with fast bio -absorbable polymer.
The aim of this study was to evaluate the performance of the sirolimus eluting stent with bio -absorbable polymer (MiStent SES) compared with zotarolimus eluting stent with permanent polymer (Endeavor). This 2:1 randomized, multicenter study included 183 patients with the primary objective of evaluating the late lumen loss between the MiStent and Endeavor a two...
SORT-OUT V: Similar results of biolimus eluting stent with biodegradable polymer versus sirolimus eluting stent with permanent polymer.
The last results of the SORT OUT V submitted in PCR 2012 showed that biolimus eluting stent with biodegradable polymer was not able to reach the non-inferiority versus sirolimus eluting stent with permanent polymer. Results to 3 years are now available, and the new device reached the non-inferiority with a MACE rate of 11.2% for...
ZEUS Trial: Patients with increased risk of bleeding may benefit from eluting stents Zotarolimus
The use of drug-eluting stents versus bare metal stents is controversial in some clinical situations in patients at high risk of bleeding.This study randomized 1606 patients considered at low risk of restenosis but with high risk of bleeding receiving Zotarolimus eluting stent (Endeavor) or conventional stent.The clinical characteristics were similar between the two groups with...
SORT OUT V: Comparison of drug-eluting stents: One with degradable polymer releasing biolimus and the other a permanent polymer sirolimus stent.
SORT OUT V randomized trial (Odense University Hospital, Denmark) compared Nobori stent, a drug-eluting stent with biodegradable polymer eluting biolimus, versus CYPHER a drug-eluting stent with permanent polymer in the real world. Danish researchers used a non-inferiority design, by means of a primary objective of the study, the combined rate of major cardiac events (cardiac...
EVOLUTION: Comparative study of non-inferiority of two sirolimus eluting stents: One with permanent polymer and the other with degradable polymer.
The EVOLUTION study, (Dr. Junbo Ge, Shanghai Institute, China), compared two sirolimus-eluting stents, one with permanent polymer (Cypher Select, Cordis Corporation, Miami Lakes, Florida, USA) and another with degradable polymer (Excel, JW Medical System Ltd, Weihai, China). A randomized (2:1) was used, open and non-inferiority, including 1923 patients in 30 centers in China (December 2008...
COMPARE II: A randomized prospective study compared the permanent polymer everolimus-eluting stent with a biodegradable polymer biolimus coated stent.
Randomized prospective study comparing the everolimus-eluting polymer-coated stent versus a biodegradable polymer with biolimus coated stent. While the use of first generation DES effectively reduces restenosis and reintervention rates, several meta-analyzes have shown a higher rate of late events of thrombotic origin associated with inflammatory phenomena and delayed reendothelialization at the site of implantation compared...